Holen Sie sich die Stockscreener-App
10.33
3.64%
-0.39
Vorhandelsmarkt:
10.11
-0.22
-2.13%
Schlusskurs vom Vortag:
$10.72
Offen:
$10.22
24-Stunden-Volumen:
3.49M
Relative Volume:
2.72
Marktkapitalisierung:
$226.34M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-112.46M
KGV:
-6.2988
EPS:
-1.64
Netto-Cashflow:
$-99.89M
1W Leistung:
+21.39%
1M Leistung:
-45.05%
6M Leistung:
+125.05%
1J Leistung:
-48.86%
1-Tages-Spanne:
$9.8301
$10.58
1-Wochen-Bereich:
$7.91
$12.82
52-Wochen-Spanne:
$2.622
$65.80
Vor Biopharma Inc Stock (VOR) Company Profile
Firmenname
Vor Biopharma Inc
Sektor
Branche
Telefon
617-655-6580
Adresse
500 BOYLSTON STREET, BOSTON
Vergleichen Sie VOR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
10.33 | 234.88M | 0 | -112.46M | -99.89M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-25 | Fortgesetzt | Wedbush | Neutral |
| 2025-10-15 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-09-24 | Hochstufung | Stifel | Hold → Buy |
| 2025-06-30 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-07-26 | Eingeleitet | Wedbush | Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Neutral |
| 2021-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-12-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-12-02 | Eingeleitet | Oppenheimer | Outperform |
| 2021-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-03-25 | Eingeleitet | B. Riley Securities | Buy |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-03-03 | Eingeleitet | Evercore ISI | Outperform |
| 2021-03-02 | Eingeleitet | Goldman | Sell |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
Alle ansehen
Vor Biopharma Inc Aktie (VOR) Neueste Nachrichten
Vor Biopharma: J.P. Morgan Makes Bull Case After Corporate Actions Slam Stock Price (VOR) - Seeking Alpha
Vor Biopharma (VOR): Valuation Check After Positive Telitacicept Phase 3 Data and Upbeat JPMorgan Coverage - Yahoo Finance
Vor Biopharma’s Recent Developments: Stock Impact Analyzed - StocksToTrade
Biotech stock soars 40% on JPMorgan’s bold call - Rolling Out
Vor Biopharma (VOR) Surges on J.P. Morgan's Bullish Outlook - GuruFocus
Vor Bio stock gains bullish view at J.P. Morgan (VOR:NASDAQ) - Seeking Alpha
Vor Biopharma (VOR) Stock Surges as JPMorgan Just Made a Massive Call on This Biotech - parameter.io
Vor Biopharma’s Telitacicept: A Promising Buy Amidst Valuation Disconnect and Strategic Focus on Unmet Needs - TipRanks
Vor Biopharma Stock Surge: Strategic Move or Short-Lived Spike? - timothysykes.com
Vor Biopharma reprices stock options for employees and executives By Investing.com - Investing.com South Africa
VOR shares rally over 40% in pre-market trade after JPMorgan initiates bullish coverage - MSN
Vor Biopharma (NASDAQ:VOR) Now Covered by Analysts at JPMorgan Chase & Co. - MarketBeat
Vor Biopharma Approves Stock Option Repricing Plan - TipRanks
Vor Biopharma reprices stock options for employees and executives - Investing.com
VOR Shares Rally Over 40% In Pre-Market Trade After JPMorgan Initiates Bullish Coverage - Stocktwits
JPMorgan Initiates Vor Biopharma at Overweight With $43 Price Target - marketscreener.com
Pre Market Movers: XCUR, VOR, MTVA Set The Path - RTTNews
JP Morgan Initiates Coverage on Vor Biopharma (VOR) with Overwei - GuruFocus
Vor Bio jumps as J.P.Morgan initiates with 'overweight' rating - TradingView
Vor Bio initiated with an Overweight at JPMorgan - TipRanks
JPMorgan initiates Vor Biopharma stock with Overweight rating, $43 target By Investing.com - Investing.com South Africa
JPMorgan initiates Vor Biopharma stock with Overweight rating on telitacicept potential - Investing.com
JPMorgan initiates Vor Biopharma stock with Overweight rating, $43 target - Investing.com
Vor Biopharma (NASDAQ:VOR) Expands Innovation In Hematologic Therapy - Kalkine Media
JPMorgan Starts Vor Biopharma, Inc. (VOR) at Overweight - StreetInsider
Profit Review: Will Vor Biopharma Inc stock maintain momentum in 2025 - BỘ NỘI VỤ
Vor Biopharma slumps 26%, prices $100M equity at $10 per share - MSN
Will Vor Biopharma Inc. stock maintain momentum in 2025Gold Moves & Capital Efficiency Focused Strategies - Newser
What drives Vor Biopharma Inc stock priceEarnings Surprise Analysis & Superior Capital Trading Plans - earlytimes.in
Is There An Opportunity With Vor Biopharma Inc.'s (NASDAQ:VOR) 49% Undervaluation? - Yahoo Finance
Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Form 424B3 Vor Biopharma Inc. - StreetInsider
Wedbush Predicts Vor Biopharma's Q4 Earnings (NASDAQ:VOR) - MarketBeat
How Vor Biopharma Inc. stock benefits from global expansionLayoff News & Fast Exit and Entry Strategy Plans - BỘ NỘI VỤ
Wedbush Begins Coverage on Vor Biopharma (NASDAQ:VOR) - MarketBeat
Vor Biopharma (VOR) Upgraded to Buy: Here's What You Should Know - sharewise.com
Wedbush Initiates Coverage on Vor Biopharma (VOR) with Neutral R - GuruFocus
Wedbush Boosts Price Target on Vor Biopharma to $9 From $0.40, Keeps Neutral Rating - marketscreener.com
Wedbush Assumes Vor Biopharma, Inc. (VOR) at Neutral - StreetInsider
Vor Biopharma Inc. (VOR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will Vor Biopharma Inc. stock attract more institutional investorsWeekly Trade Review & Capital Efficiency Focused Strategies - newser.com
Why retail investors favor Vor Biopharma Inc. stock2025 Technical Patterns & Free Community Supported Trade Ideas - newser.com
What technical signals suggest for Vor Biopharma Inc. stockQuarterly Profit Summary & Verified Momentum Stock Alerts - newser.com
Combining price and volume data for Vor Biopharma Inc.2025 Big Picture & Technical Confirmation Alerts - newser.com
How currency fluctuations impact Vor Biopharma Inc. stockFed Meeting & Real-Time Buy Signal Alerts - newser.com
Can a trend reversal in Vor Biopharma Inc. lead to recoveryWeekly Trade Summary & Low Risk Growth Stock Ideas - newser.com
Using data models to predict Vor Biopharma Inc. stock movementJuly 2025 Pullbacks & Low Drawdown Momentum Ideas - newser.com
Using Python tools to backtest Vor Biopharma Inc. strategiesJuly 2025 News Drivers & Daily Profit Maximizing Tips - newser.com
Forecasting Vor Biopharma Inc. price range with options dataAnalyst Upgrade & Stepwise Trade Execution Plans - newser.com
Finanzdaten der Vor Biopharma Inc-Aktie (VOR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):